SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

CELC

Celcuity Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 8h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor Q4 2026 for first product revenue recognition and early prescription trends; the sNDA decision for the PIK3CA mutant cohort and VIKTORIA-2 enrollment updates are key catalysts. Cash runway through 2029 removes near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonweeks

REVTORPYK

◆ Mixed Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
Next catalyst
None dated

What to watchWatch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$66.79
T+0 close · Nov 5, 2026 · via day close
Latest settled
−3.62%
T+5 · $64.37
Vs SPY
−6.22%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $66.79entry
  2. T+1 · 8d ago +5.36%α +2.99% · $70.37
  3. T+5 · 4d ago −3.62%α −6.22% · $64.37
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celcuity reported Q3 2026 GAAP net loss of $1.33 per share, wider than the $1.53 consensus estimate (a beat), and no product revenue as REVTORPYK shipments began on September 30 but product was not received by customers until after quarter-end. The company highlighted a strong early launch with 78% of top strategic accounts ordering REVTORPYK and 91% commercial/Medicare coverage, while cash runway extends through 2029.

Key Financial Metrics

EPS (Adj.)
−$1.21
est −$1.53 · +20.9% · GAAP: $-1.33
Revenue
$0.00
est $517.0K · -100.0%
Rating
in line

Key Facts

  • GAAP net loss $73.3M ($1.33/share) vs $43.8M ($0.92/share) year ago
  • Non-GAAP adjusted net loss $66.8M ($1.21/share) vs $37.2M ($0.78/share) year ago
  • No product revenue recognized in Q3; first REVTORPYK shipments began Sep 30
  • Total operating expenses $77.3M, up from $42.8M, driven by commercial buildout
  • Cash, equivalents and investments $642.7M; expected to fund operations through 2029
  • 91% of U.S. commercial and Medicare lives covered for REVTORPYK
  • 78% of top 36 strategic accounts have ordered REVTORPYK
  • sNDA for PIK3CA mutant cohort submitted to FDA in Q3 2026
  • VIKTORIA-2 Phase 3 trial enrollment ongoing in first-line HR+/HER2- ABC

Financial Impact

Net loss widened by $29.5M YoY; operating expenses nearly doubled to $77.3M due to commercial launch costs; cash burn $66.2M in operating activities plus $50M milestone payment to Pfizer

net lossoperating expensescash burnno product revenue

Risk Factors

  • No product revenue yet; commercial ramp may be slower than expected
  • sNDA for PIK3CA mutant cohort faces FDA review risk
  • Competition from alpelisib and other PI3K/AKT/mTOR inhibitors
  • High cash burn rate ($66.2M operating cash flow in Q3) may accelerate if launch costs persist

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396999

Track record

26 reports on CELC

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
  3. Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
  7. Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
  8. Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
  9. Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
  10. Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026